Linc AB Discloses Large Shareholding in Oncoinvent ASA
Linc AB has announced a significant shareholding in Oncoinvent ASA. The disclosure follows the company's completion of a share offering in September 2026.
Linc AB has disclosed a substantial shareholding in the oncology-focused company Oncoinvent ASA. The announcement was made on October 2, 2026.
The disclosure is related to Oncoinvent ASA's private placement and retail offering, which concluded in September 2026. The company issued a total of 1,650,000 new shares at a subscription price of NOK 90 per share. Linc AB received a significant allocation of these newly issued shares.
In connection with the share offering, Linc AB had also temporarily lent 555,362 existing and unencumbered shares. The exact size of the shareholding and its implications for the company's governance or strategy are yet to be fully detailed.
Oncoinvent ASA is engaged in the development of cancer therapeutics. The timing of this significant investment may signal the investor's confidence in the company's future prospects.